Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. [electronic resource]
Producer: 20150721Description: 1091-101 p. digitalISSN:- 1538-7445
- Animals
- Disease Models, Animal
- Humans
- MAP Kinase Signaling System
- Mice
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Pancreatic Neoplasms -- drug therapy
- Phosphatidylinositol 3-Kinases -- physiology
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins c-akt -- physiology
- Proto-Oncogene Proteins p21(ras) -- genetics
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Signal Transduction -- physiology
- TOR Serine-Threonine Kinases -- physiology
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.